Phenotypes Associated with This Genotype

Genotype
MGI:5447021

• Allelic Composition: Kmt2a^{tm1(MLL1/ERT)Divo}/?
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:189329 )

• in some tamoxifen-treated mice (mean survival 592 days)

• mice treated with caffeine and tamoxifen do not survive beyond 100 days (mean survival 62 days)

immune system

enlarged spleen ( J:189329 )

• severe in mice treated with caffeine and tamoxifen

myeloid hyperplasia ( J:189329 )

• after 7 months of tamoxifen treatment, all mice exhibit myeloproliferative disease in the bone marrow and spleen

• tamoxifen-treated mice exhibit myeloid hyperproliferation followed by induction of cellular senescence more robustly in the bone marrow than spleen

neoplasm

increased acute promyelocytic leukemia incidence ( J:189329 )

• caffeine treatment facilitates acute myeloid leukemia development in tamoxifen-treated mice

• caffeine treatment of tamoxifen-treated mice promotes acquisition of self-renewal capacity and enables development of leukemia stem cells

liver/biliary system

enlarged liver ( J:189329 )

• severe in mice treated with caffeine and tamoxifen

hematopoietic system

enlarged spleen ( J:189329 )

• severe in mice treated with caffeine and tamoxifen

myeloid hyperplasia ( J:189329 )

• after 7 months of tamoxifen treatment, all mice exhibit myeloproliferative disease in the bone marrow and spleen

• tamoxifen-treated mice exhibit myeloid hyperproliferation followed by induction of cellular senescence more robustly in the bone marrow than spleen

growth/size/body

enlarged liver ( J:189329 )

• severe in mice treated with caffeine and tamoxifen

enlarged spleen ( J:189329 )

• severe in mice treated with caffeine and tamoxifen